Mendus AB

📍 Stockholm, Sweden👥 34 employees💰 Last funded Jan 2021
Biotechnology Research🌐 mendus.com
Website LinkedIn
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
Netherlands
1
Frequently asked questions
Who invested in Mendus AB?
Mendus AB has 2 investors on record on gritt.io.
When did Mendus AB last raise funding?
The most recent investment in Mendus AB recorded on gritt.io was in January 2021.
What industry is Mendus AB in?
Mendus AB operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Mendus AB based?
Mendus AB is headquartered in Stockholm, Sweden.